Početna › Burkittov limfom › Massachusetts
Kliničke studije za Burkittov limfom u državi Massachusetts
10 studija za Burkittov limfom traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
U tijeku regrutacijaFaza 2
366 Days – 46 Years · Oba spola · Ažurirano 2. lis 2026. · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 3
Od 18 do 39 godina · Oba spola · Ažurirano 2. lis 2026. · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
U tijeku regrutacijaFaza 2
365 Days · Oba spola · Ažurirano 25. ruj 2026. · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT06395103Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- i još 1
U tijeku regrutacijaFaza 3
365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 4. stu 2025. · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 15 do 50 godina · Oba spola · Ažurirano 9. ruj 2025. · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Floating Hospital for Children at Tufts Medical Center, Boston
- Dana Faber Cancer Institute/ Boston Children's Hospital, Boston
U tijeku regrutacijaFaza 2
Od 1 do 25 godina · Oba spola · Ažurirano 4. svi 2025. · NCT03509961Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.